Although the underlying mechanisms of cyclophilin A on cancer development remain elusive, cyclophilin A inhibitors (especially CsA) have emerged for possibilities to treat human malignancies, including hematological and solid cancers, in clinical trials [78,79,172,173]. The gene discussed is PPIA; the disease is cancer.